Doxazosin Tablet
Product Images NDC 71335-2322

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71335-2322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Doxazosin-structure.jpg (Doxazosin Structure)
Chemical structure of doxazosin, displaying its molecular arrangement with rings and functional groups, including methoxy groups and piperazine, consistent with the active ingredient doxazosin.*
FDA Label Image

Figure1.jpg (Figure1)

Figure1.jpg (Figure1)
This image features two line graphs comparing Doxazosin and placebo effects over 14 weeks. The left graph shows mean change in total symptom score from baseline, with Doxazosin consistently reducing symptoms more than placebo. The right graph depicts mean increase in maximum urinary flow rate from baseline, with Doxazosin showing greater improvement than placebo. Both graphs include statistical significance markers.*
FDA Label Image

Label (Lbl713352322)

Label (Lbl713352322)
Label for Doxazosin Tablets, USP, 4 mg oral tablets. Packaged in a container of 100 tablets. Labeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Apotex Inc. The package is child-resistant and includes storage instructions for controlled room temperature.*
FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
This image presents a summary of effectiveness data from placebo-controlled clinical trials of Doxazosin. It shows symptom scores and maximum flow rate changes for placebo and Doxazosin across three studies with various dosages and durations. The accompanying bar graph illustrates mean changes in maximum flow rate and symptom scores for placebo, 4 mg, and 8 mg Doxazosin doses in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.